Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
McKesson
Express Scripts
Johnson and Johnson
Medtronic

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021642

See Plans and Pricing

« Back to Dashboard

NDA 021642 describes NASCOBAL, which is a drug marketed by Par Pharm and Endo Pharms Inc and is included in two NDAs. It is available from one supplier. There are six patents protecting this drug and one Paragraph IV challenge. Additional details are available on the NASCOBAL profile page.

The generic ingredient in NASCOBAL is cyanocobalamin. There are nine drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the cyanocobalamin profile page.
Summary for 021642
Tradename:NASCOBAL
Applicant:Endo Pharms Inc
Ingredient:cyanocobalamin
Patents:6
Formulation / Manufacturing:see details
Pharmacology for NDA: 021642
Suppliers and Packaging for NDA: 021642
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NASCOBAL cyanocobalamin SPRAY, METERED;NASAL 021642 NDA Par Pharmaceutical, Inc. 49884-270 49884-270-82 4 SPRAY in 1 CARTON (49884-270-82)
Paragraph IV (Patent) Challenges for 021642
Tradename Dosage Ingredient NDA Submissiondate
NASCOBAL SPRAY, METERED;NASAL cyanocobalamin 021642 2017-04-28

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;NASALStrength0.5MG/SPRAY
Approval Date:Jan 31, 2005TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Aug 1, 2024Product Flag?YSubstance Flag?Delist Request?
Patented Use:NASAL ADMINISTRATION OF CYANOCOBALAMIN
Patent:  Start TrialPatent Expiration:Mar 12, 2024Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Aug 1, 2024Product Flag?YSubstance Flag?Delist Request?
Patented Use:CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Merck
Boehringer Ingelheim
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.